Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) — Medicare Part D spending
Multiple manufacturers (10) · Rank #347 by total Part D spend · CMS data year 2023
Medicare Part D spent $118,183,005 on Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) in 2023, the #347 drug by total Part D spending out of 3,598 drugs. That worked out to about $0.29 per dosage unit, $23 per claim and $86 per beneficiary, across 5,189,215 claims for 1,380,777 beneficiaries. Average spending per dosage unit rose +10.8% from 2022. These are aggregate Medicare program figures (gross drug cost), not the price you pay.
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) spending at a glance (2023)
| Metric | Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) |
|---|---|
| Total Part D spending (2023) | $118,183,005 |
| Total spending (2022) | $97,508,398 |
| Year-over-year change in total spending | +21.2% |
| Average spending per dosage unit (2023) | $0.29 |
| Change in spend per dosage unit (YoY) | +10.8% |
| Avg annual change per dosage unit (2019-2023 CAGR) | +9.9% |
| Average spending per claim (2023) | $23 |
| Average spending per beneficiary (2023) | $86 |
| Total claims (2023) | 5,189,215 |
| Beneficiaries (2023) | 1,380,777 |
| Total dosage units (2023) | 408,994,375 |
| Manufacturer(s) | Multiple manufacturers (10) |
| National rank by total spend (of 3,598 drugs) | #347 |
Source: CMS Medicare Part D Spending by Drug (data year 2023). Data as of June 2026.
2022 vs 2023
| Metric | 2022 | 2023 | Change |
|---|---|---|---|
| Total spending | $97,508,398 | $118,183,005 | +21.2% |
| Avg spend per dosage unit | $0.26 | $0.29 | +10.8% |
| Avg spend per claim | $20 | $23 | — |
| Avg spend per beneficiary | $76 | $86 | — |
| Total claims | 4,777,968 | 5,189,215 | — |
| Beneficiaries | 1,282,789 | 1,380,777 | — |
How Losartan-Hydrochlorothiazide compares with nearby drugs
Drugs with total Part D spending closest to Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide):
| Drug (rank) | Total spend 2023 | Per dosage unit | Per-unit YoY |
|---|---|---|---|
| Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) (this drug, #347) | $118,183,005 | $0.29 | +10.8% |
| Trulance (Plecanatide) (#345) | $119,272,260 | $18.72 | +7.4% |
| Idhifa (Enasidenib Mesylate) (#346) | $118,905,343 | $1,086.10 | +7.1% |
| Vyndaqel (Tafamidis Meglumine) (#348) | $118,169,381 | $181.48 | +5.3% |
| Vyzulta (Latanoprostene Bunod) (#349) | $117,369,728 | $100.85 | +7.3% |
| Doxycycline Hyclate* (Doxycycline Hyclate) (#350) | $117,340,524 | $0.80 | -13.5% |
Frequently asked questions
How much does Medicare Part D spend on Losartan-Hydrochlorothiazide?
Medicare Part D spent $118,183,005 on Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) in 2023 (the latest CMS data year), across 5,189,215 claims for 1,380,777 beneficiaries. That ranks #347 of 3,598 drugs by total Part D spending. This is gross drug cost (Medicare, plan and beneficiary payments combined), not the price you personally pay.
What is the average spending per dosage unit for Losartan-Hydrochlorothiazide?
In 2023, the weighted average Medicare Part D spending per dosage unit for Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) was $0.29. Compared with 2022 it rose +10.8%. A "dosage unit" is one pill, tablet, milliliter or other billing unit, so this is not the price of a prescription.
Who makes Losartan-Hydrochlorothiazide?
CMS attributes Losartan-Hydrochlorothiazide (Losartan/Hydrochlorothiazide) to Multiple manufacturers (10) in the 2023 Part D spending file. Average spending per claim was $23 and per beneficiary $86.
Is the Losartan-Hydrochlorothiazide figure the price I pay?
No. These are aggregate Medicare Part D program figures (total gross drug cost and averages across all claims), published by CMS for transparency. Your out-of-pocket cost depends on your plan, formulary, deductible and coverage phase. Always check your plan and talk to your pharmacist or doctor.
Keep exploring
Source & what this means
Figures are from the CMS Medicare Part D Spending by Drug dataset (data year 2023, US public domain). "Total spending" is the gross drug cost — Medicare, plan and beneficiary payments combined — for Part D claims; it is not a list price, a negotiated price, or what any individual pays. Spending per dosage unit is volume-weighted across formulations. This is general public-spending information, not medical or pricing advice. Your own cost depends on your plan, deductible and coverage phase — verify with your Part D plan and a pharmacist. Data as of June 2026. See our methodology and disclaimer.
Last updated: 2026-06-20